Skip to content
Buy This GLP
← Research
Evidence

Semaglutide 2.4 mg Medical Costs in Adherent Patients: 22% Lower

One claims study found 22% lower medical costs among adherent semaglutide users with cardiovascular disease than among matched controls.

Editorial profile: Neil SandersBuy This GLP Editorial Team5 min read
Lower than matched controls, over one yearall medical costs−22%inpatient costs−65%inpatient visits−48%Treated cohort = patients who stayed adherent for the year

Studies of total spending including prescription costs answer a broader question than a comparison of medical bills. SHINE-ASCVD examined one year of medical costs in adults with existing cardiovascular disease [1].

Who was compared

The U.S. claims study matched 770 adults using semaglutide 2.4 mg to 3,080 controls. All had overweight or obesity and atherosclerotic cardiovascular disease. The treated group had prescription coverage on at least 80% of follow-up days [1].

Mean annual medical costs were $16,201 with semaglutide and $20,840 in controls. The modeled ratio was 0.78 (95% CI 0.67 to 0.89). Inpatient costs accounted for much of the observed difference [1].

What the cost difference means

Selecting patients by later adherence can favor those able to stay on treatment. Matching at baseline cannot account for all differences. The study did not establish net savings after adding the price of treatment.

Evidence on cardiovascular outcomes in randomized trials comes from a different study design. A change in event risk still leaves a separate question about drug spending and who pays it.

Novo Nordisk funded SHINE-ASCVD. These are medical cost estimates for a selected insured population.

Frequently asked

How much lower were annual medical costs?
The recorded averages differed by $4,639 per person. The observational study cannot establish that semaglutide caused the difference.

Sources

  1. [1] Michalak W, et al. (2025). Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD) Journal of Medical Economics. PMID 40579810

Where to get it

The cheapest GLP-1

Every seller that publishes a price, ordered lowest first on the standing month-to-month rate, plus the question to ask before you pay any of them.

See the board →

More in Evidence